Dense Breasts: Should You Get Extra Screening?

If your mammogram report says your breast tissue is "heterogeneously dense" or "extremely dense," and your imaging center now includes a federally required notification about it, the next patient question is almost always the same: do I need a second test on top of my mammogram? This guide walks through what dense breasts mean, what supplemental screening adds, and how 2026 guidelines help you decide.

Key Takeaways

• About 40% to 50% of women aged 40 to 74 in the United States have dense breasts (BI-RADS density category C or D).
• Since September 2024, the FDA requires every mammogram facility to tell patients in writing if their breast tissue is dense and to mention that supplemental imaging may help.
• Supplemental whole-breast ultrasound finds about 2 to 4 additional cancers per 1,000 screened women; supplemental MRI finds 10 to 16 additional cancers per 1,000 women in the highest-risk groups.
• Dense tissue is normal, not a disease, but it can hide cancer on mammograms and slightly raises lifetime breast cancer risk.
• 2026 guidelines from the American College of Radiology and the Society of Breast Imaging support offering MRI to women with extremely dense breasts, while ACOG and USPSTF do not recommend routine supplemental imaging based on density alone.

What "Dense Breasts" Actually Means

Breast density is a description of how breast tissue looks on a mammogram, not how the tissue feels. Glandular (milk-producing) and fibrous tissue appear white on the X-ray. Fat appears dark gray. Women with more glandular and fibrous tissue have dense breasts — and so does a possible cancer, which is why dense tissue can mask small tumors.

The American College of Radiology (ACR) defines four breast density categories in its BI-RADS lexicon, which appears on every U.S. mammogram report:

Categories C and D are what most reports and laws refer to as "dense." For a deeper look at category B, see our guide to scattered fibroglandular density.

Why Density Matters for Cancer Detection

Two things change when breasts are dense:

1. Mammogram sensitivity drops. In fatty breasts, mammography finds about 90% of cancers. In extremely dense breasts, sensitivity falls to roughly 60% to 70%. A normal mammogram in dense tissue is reassuring, but less so than in fatty tissue.
2. Baseline risk rises modestly. Women with extremely dense breasts have about a 1.2 to 2 times higher relative risk of breast cancer compared with women with average density, after accounting for age. The relative risk is real but small in absolute terms.

These two effects are why physicians and advocacy groups have pushed for supplemental imaging options. The American Cancer Society notes that dense breast tissue is a meaningful but not isolated risk factor — your overall risk profile (family history, prior biopsy, genetic mutations) matters more than density alone.

The FDA Notification Rule

In March 2023 the FDA updated the Mammography Quality Standards Act (MQSA) to require nationwide density notification, with the rule taking effect on September 10, 2024. Every imaging facility in the United States must now:

• Include your specific breast density category on the lay-language summary mailed to you.
• State that dense tissue can hide cancer and increase cancer risk.
• Mention that supplemental imaging may help, and suggest discussing options with your doctor.

The notification is the same for every patient with category C or D. It is not a diagnosis or a personalized recommendation — your doctor and imaging center personalize what comes next.

Supplemental Ultrasound: What It Adds

Whole-breast ultrasound uses sound waves to image breast tissue. It is widely available, has no radiation, and is generally well tolerated. In dense breasts, supplemental ultrasound has been shown to detect 2 to 4 additional cancers per 1,000 screened women beyond what mammography catches.

The trade-offs:

• False positives rise. Many women called back for ultrasound findings are eventually shown to have a benign lesion or normal tissue.
• Operator skill varies. Hand-held ultrasound depends on the technician and radiologist. Automated breast ultrasound (ABUS) standardizes the exam and is FDA-approved for supplemental screening.
• Cost and coverage vary. Some U.S. states require insurance coverage for supplemental ultrasound after a dense-breast notification; others do not.

The Society of Breast Imaging (SBI) considers ultrasound a reasonable option when MRI is not available or not tolerated.

Supplemental MRI: What It Adds

Breast MRI is the most sensitive screening test available. In women with extremely dense breasts and average other risk, the DENSE trial published in the New England Journal of Medicine found that adding MRI to mammography detected about 16.5 cancers per 1,000 screens in the MRI arm, compared with 6.0 per 1,000 in the mammography-only arm — and most of the MRI-detected cancers were small and node-negative.

The trade-offs:

• MRI is the most sensitive but also the most expensive. Out-of-pocket cost ranges from a few hundred to over a thousand dollars without insurance coverage.
• It requires contrast. Most screening MRIs use a gadolinium-based contrast agent. People with severe kidney disease or a prior gadolinium reaction may not be candidates.
• Not everyone can have one. About 1 in 5 women in screening cohorts cannot tolerate MRI because of claustrophobia, certain implants, or contrast issues.
• False positives are higher. Roughly 1 in 10 screened women are recalled for additional workup.

For context on the procedure itself, see MRI with contrast vs. without contrast.

What 2026 Guidelines Recommend

Major U.S. guideline bodies do not fully agree on supplemental screening, which is why your doctor's recommendation matters more than any single rule.

• ACR and SBI (2024–2026 updates) support offering supplemental MRI to women with extremely dense breasts (category D) and considering it for heterogeneously dense breasts (category C) in combination with other risk factors.
• NCCN 2026 Guidelines added AI-mammogram-based 5-year risk assessment starting at age 35 to identify dense-breast women who may benefit from supplemental imaging. See our AI mammogram screening guide.
• USPSTF (2024) concluded that current evidence is "insufficient" to recommend supplemental imaging for asymptomatic women with dense breasts and no other risk factors. The Task Force did not advise against it — they simply did not endorse it.
• ACOG does not recommend routine supplemental imaging based on density alone in average-risk women.

The practical result: if you are at higher overall risk (family history, BRCA1/BRCA2 mutation, prior chest radiation), supplemental MRI is broadly supported. If you are average risk with only dense breasts, the decision is shared between you and your doctor.

Questions to Ask Your Doctor

When you discuss your dense-breast notification, bring these questions:

1. What is my overall lifetime breast cancer risk, based on family history and other factors?
2. Given my density category and risk, do you recommend supplemental ultrasound, MRI, both, or watchful waiting?
3. Is supplemental imaging covered by my insurance? What is my out-of-pocket cost?
4. If we do MRI, will it be done with contrast? Is my kidney function adequate?
5. How often should I screen — annually or every other year?

For more on how to make these conversations productive, see our guide on how to discuss imaging results with your doctor.

Frequently Asked Questions

Does having dense breasts mean I have cancer or will get cancer?

No. Dense tissue is normal breast composition seen in roughly half of women aged 40 to 74. It modestly raises baseline breast cancer risk (about 1.2 to 2 times the average-density baseline) and reduces mammogram sensitivity, but it is not a disease and most women with dense breasts never develop breast cancer.

Should every woman with dense breasts get a supplemental MRI?

No. Major guideline bodies disagree. ACR and SBI support offering MRI to women with extremely dense breasts (category D) and to dense-breast women with elevated overall risk. USPSTF and ACOG do not recommend routine supplemental imaging based on density alone. The right choice depends on your overall risk profile and your tolerance for false-positive recall.

Is supplemental screening covered by insurance?

Coverage varies by state and plan. As of 2026, more than 30 U.S. states have enacted insurance laws requiring some coverage of supplemental screening after a dense-breast notification, but the scope of what is covered (ultrasound only, MRI, both) and patient cost-sharing differ. Call your insurer before scheduling. Federal Affordable Care Act coverage applies only to the screening mammogram, not to supplemental tests.

Does an AI mammogram replace the need for supplemental screening?

Not by itself. AI tools that read mammograms can detect more cancers and provide a 5-year risk estimate, but the resulting risk score is one input into a supplemental-screening decision, not a substitute for ultrasound or MRI in women who would benefit from either. Learn more in our AI mammogram patient guide.

Where can I learn more about my mammogram report?

Start with our BI-RADS guide, the scattered fibroglandular density explainer, and the breast calcifications guide.

Related Articles

• How to Read a Mammogram Report: BI-RADS Guide
• AI in Mammograms: How It Helps Detect Breast Cancer
• Scattered Fibroglandular Density on Mammogram Explained

---

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment decisions.